# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Proposed Single Technology Appraisal**

# Vortioxetine for the treatment of major depressive disorder

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
	арреату
Manufacturers/sponsors	General
Lundbeck and Takeda	Allied Health Professionals Federation
Pharmaceuticals (vortioxetine)	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
Patient/carer groups	<ul> <li>British National Formulary</li> </ul>
Afiya Trust	Care Council for Wales
Black Health Agency	Care Quality Commission
Black Mental Health UK	<ul> <li>Commissioning Support Appraisals</li> </ul>
• C.A.L.M	Service
• Changes	Department of Health, Social Services
Charlie Waller Memorial Trust	and Public Safety for Northern Ireland
Chinese Mental Health Association     Carehat Stress	Hafal     Incompany and a second a second and a second a second and a second a second and a
Combat Stress	Journeys     Jacks Journeys
Counsel and Care  Page 2012 Alliance  Pag	Health Improvement Scotland     Madisings and Userth some products
Depression Alliance     Depression LIK	Medicines and Healthcare products     Pagulaton, Agency
Depression UK     Fauglities National Council	Regulatory Agency  Mental Health Act Commission
<ul><li>Equalities National Council</li><li>Matthew Trust</li></ul>	MIND Cymru
Max Appeal	National Association of Primary Care
Mental Health Foundation	National Mental Health Development
Mental Health Matters	Unit
Mental Health Providers Forum	National Pharmacy Association
MIND	NHS Alliance
Muslim Council of Britain	NHS Commercial Medicines Unit
Muslim Health Network	NHS Confederation
National Perceptions Forum	Public Health Wales NHS Trust
Papyrus	Scottish Medicines Consortium
Race Equality Foundation	Social Care Institute for Excellence
Rethink Mental Health	
• SANE	Possible comparator manufacturers
South Asian Health Foundation	Abbott (fluvoxamine)
Specialised Healthcare Alliance	Accord Healthcare (amitriptyline,
Together	citalopram, fluoxetine and sertraline)
United Response	Actavis (amitriptyline, citalopram,
WISH – A voice for women's mental	clomipramine, fluoxetine, imipramine, lofepramine, mirtazapine, paroxetine,
health	ioreprairine, minazapine, paroxetine,

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of vortioxetine for the treatment of major depressive disorder

Issue date: September 2012

#### Consultees Commentators (no right to submit or appeal) Professional groups sertraline, trazodone and venlafaxine) Arrow Generics (amitriptyline, British Association for Counselling and citalopram, lofepramine, mirtazapine, Psychotherapy sertraline and venlafaxine) British Association for Aurobindo Pharma (citalopram, Psychopharmacology mirtazapine, paroxetine and sertraline) British Association for Services to the Elderly Bluefish Pharmaceuticals (mirtazapine and venlafaxine) **British Association for Social Workers** Bristol Laboratories (citalogram, British Association of Behavioural and sertraline and venlafaxine) Cognitive Psychotherapies Chiesi (venlafaxine) British Association of **Psychotherapists** Creo Pharma (mirtazapine and British Confederation of venlafaxine) **Psychotherapists** Dallas Burston Ashbourne British Geriatrics Society (venlafaxine) Dexcel Pharma (venlafaxine) British Neuropsychiatry Association **British Psychological Society** Dr Reddys Labs (citalopram, fluoxetine and venlafaxine) College of Mental Health Pharmacy GlaxoSmithKline (paroxetine) College of Occupational Therapists Genus Pharmaceuticals (venlafaxine) Community Psychiatric Nurses King Pharmaceuticals (nortriptyline) Association • Counsellors and Psychotherapists in Lilly UK (duloxetine and fluoxetine) Lundbeck (citalopram, escitalopram) **Primary Care** Clifford Beers Foundation Lupin Pharmaceuticals (imipramine and sertraline) General Social Care Council Marlborough (doxepin) Mental Health Nurses Association Merck Sharp & Dohme (mirtazapine) Primary Care Mental Health Education Mercury Pharma (trazodone and Royal College of General Practitioners venlafaxine) Royal College of Nursing Mylan (citalopram, clomipramine, Royal College of Pathologists fluoxetine, lofepramine, mianserin, Royal College of Physicians mirtazapine, paroxetine, sertraline, Royal College of Psychiatrists trazodone and venlafaxine) Royal Pharmaceutical Society Niche Generics (citalopram, fluoxetine Royal Society of Medicine and venlafaxine) United Kingdom Clinical Pharmacy Novartis (imipramine and Association clomipramine) United Kingdom Council for Pfizer (amitriptyline, doxepin, Psychotherapy mirtazapine, paroxetine, reboxetine, sertraline and venlafaxine) Others Pinewood Healthcare (fluoxetine)

- Cwm Taf Health Board
- Department of Health
- Bournemouth, Poole and Dorset PCT Cluster
- Welsh Government

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of vortioxetine for the treatment of major depressive disorder

Issue date: September 2012

Ranbaxy (amitriptyline, citalogram,

Sandoz (citalopram, fluoxetine,

venlafaxine)

fluoxetine, mirtazapine, sertraline and

Consultees	Commentators (no right to submit or appeal)
	<ul> <li>lofepramine, mirtazapine, paroxetine, sertraline and venlafaxine)</li> <li>Sanofi (trazodone and trimipramine)</li> <li>Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine)</li> <li>Wockhardt (amitriptyline, citalopram, fluoxetine, fluvoxamine (mirtazapine and sertraline)</li> <li>Zentiva (citalopram, fluoxetine, paroxetine, trazodone and venlafaxine)</li> </ul>
	<ul> <li>Relevant research groups</li> <li>Campbell Collaboration Social Welfare Group</li> <li>Cochrane Depression, Anxiety &amp; Neurosis GroupInstitute of Psychiatry</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>National Primary Care Research &amp; Development Centre</li> <li>Research Institute for the Care of Older People</li> </ul>
	<ul> <li>Evidence Review Group</li> <li>Evidence Review Group tbc</li> <li>National Institute for Health Research Health Technology Assessment Programme</li> </ul>
	<ul> <li>Associated Guideline groups</li> <li>National Collaborating Centre for Mental Health</li> <li>Associated Public Health groups</li> </ul>
	TBC

Issue date: September 2012 Page 3 of 4

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: September 2012 Page 4 of 4

### **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

# **Evidence Review Group (ERG)**

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of vortioxetine for the treatment of major depressive disorder

Issue date: September 2012 Page 5 of 4

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.